A new form of cell death starts inside mitochondria — and it wakes the immune system up
Edited by Samael A. Tejada, Founder & Editor-in-Chief
·Tip: press play, then lock your phone or switch apps — the article keeps reading.
For decades BAK and BAX were apoptosis proteins: they open the mitochondrial outer membrane, cytochrome c escapes, caspases switch on, and the cell dismantles itself without alarming its neighbors. A team at Memorial Sloan Kettering (MSK) and collaborators now report that the same two proteins can build a different mitochondrial death machine — one whose whole point is to be noticed.
How is baciptosis different from apoptosis?
In the second arrangement, BAK and BAX assemble with other proteins across both the outer and inner mitochondrial membranes, allowing mitochondrial DNA (mtDNA) to be released into the cytosol, the fluid inside the cell. When caspases are not activated, that escaped mtDNA triggers inflammatory responses and contributes to catastrophic energy failure — baciptosis — and a strong response from the immune system. Same proteins, different architecture, opposite social behavior: silent disposal versus an alarm bell.
Why could a louder death help cancer treatment?
Immunotherapy works when immune cells can find and attack tumors, and a quietly dying cancer cell gives them little to find. MSK notes the team demonstrated baciptosis can be induced in human cancer cells with impaired caspase activation, suggesting relevance to cancers with similar defects. Finding ways to trigger baciptosis instead of apoptosis could, in principle, help the immune system recognize and attack tumors and improve cancer immunotherapy.
What has not been shown yet?
A treatment. This is a mechanism discovered in cell work, reported through MSK's October 22, 2026 research highlights and the underlying Cell study it summarizes. No drug that selectively triggers baciptosis in patients exists, no animal treatment result is claimed in the highlight, and deliberately provoking inflammatory cell death in healthy tissue would carry obvious risks. The honest takeaway is a new, named target for cancer research — not a therapy readers can ask for.
Frequently asked questions
What is baciptosis?
Baciptosis is a newly described form of cell death in which the mitochondrial proteins BAK and BAX assemble across both mitochondrial membranes, letting mitochondrial DNA escape into the cell. That triggers inflammation and catastrophic energy failure — a loud death, unlike quiet apoptosis.
How is baciptosis different from apoptosis?
In apoptosis, BAK and BAX open only the outer mitochondrial membrane, cytochrome c escapes, caspases switch on, and the cell dismantles itself quietly. In baciptosis, the proteins form a cross-membrane arrangement, mitochondrial DNA leaks out, and — when caspases are not activated — the cell dies with inflammation that alerts the immune system.
Could baciptosis lead to a new cancer treatment?
Possibly one day, but not yet. Researchers induced baciptosis in human cancer cells with impaired caspase activation, which suggests tumors that die loudly might be easier for the immune system to find and attack. No drug triggers baciptosis in patients, and there are no animal or human treatment results.
Has baciptosis been tested in people?
No. The findings come from cell research at Memorial Sloan Kettering, highlighted on October 22, 2026. There is no baciptosis-based therapy readers can ask for today.
Where the evidence stands
- Established: BAK and BAX drive mitochondrial apoptosis by permeabilizing the outer membrane and releasing cytochrome c, activating caspases in a largely non-inflammatory death.
- Preliminary: Per MSK's October 22, 2026 highlight of the Cell work, BAK/BAX can alternatively assemble across both mitochondrial membranes, releasing mtDNA into the cytosol and — when caspases are inactive — causing inflammatory, energy-failure death (baciptosis); it was inducible in human cancer cells with impaired caspase activation.
- Absent: A drug that triggers baciptosis, animal or human treatment data, and safety evidence for provoking this death pathway in patients.
Join the discussion
To get the conversation started: What questions does this story raise for you? Share them below — every comment is reviewed by our moderators before it appears.
Community discussion only — not medical advice. Every comment is reviewed by our moderators before it appears. Sign in with Google or a free Hyvor account to join in.